# Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

> **NCT00212290** · PHASE4 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 140 (estimated)

## Conditions studied

- Insulin Resistance
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** pioglitazone
- **DRUG:** nateglinide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00212290
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2010-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00212290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00212290, "Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00212290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*